Navigation Links
ViaCyte to Present at 35th Annual Cowen and Company Health Care Conference
Date:2/25/2015

SAN DIEGO, Feb. 25, 2015 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced that Dr. Paul Laikind, President and Chief Executive Officer, will present at the 35th Annual Cowen and Company Health Care Conference as follows:

Date:

Monday, March 2, 2015

Time:

11:30 a.m. EST

Location:

Boston Marriott Copley Place

Dr. Laikind will review recent progress with the company's VC-01™ product candidate for the treatment of type 1 diabetes, which recently entered the clinical phase of development.  A Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type 1, was launched in September 2014, and the first patient was successfully implanted at UC San Diego Health System in October 2014.  

For more information about the events, please visit: http://viacyte.com/news-events-2/viactye-events/

About ViaCyte

ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.  ViaCyte is conducting a Phase 1/2 clinical trial of the Company's VC-01 lead product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function.  ViaCyte's VC-01 combination product is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells.  These progenitor cells are implanted in a durable and retrievable encapsulation device.  Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels.  The VC-01 product is being developed as a potential long-term diabetes treatment without immune suppression, and without risk of hypoglycemia or other diabetes-related complications.

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. 

 

Logo - http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a

 


'/>"/>
SOURCE ViaCyte, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. ViaCyte Granted Over 20 Patents in 2013 Further Establishing the Company as a Leader in the Field of Regenerative Medicine
2. Shire to Present at the Cowen 35th Annual Healthcare Conference
3. AbbVie to Present at Cowen 35th Annual Health Care Conference
4. GenomeDxs Decipher Shows Broad Applicability in Advancing Prostate Cancer Care in Data Presented at 2015 ASCO Genitourinary Symposium
5. Mast Therapeutics To Present At Cowen And Companys 35th Annual Healthcare Conference On March 2nd
6. BlueInGreen® Solidifies Representation in Two Key States: Virginia and Texas
7. Oxford BioTherapeutics to Present at 35th Cowen and Company Annual Health Care Conference in Boston
8. Novogen to Present at SACHS Cancer Bio Partnering & Investment Forum
9. Dr. Samuel Henderson, Acceras V.P. of Research and Development, to Present at the 249th American Chemical Society National Meeting
10. At London Predictive Toxicology Summit Asymmetrex Presents New Biotech Solutions For Earlier Identification Of Drugs Toxic To Patients’ Adult Stem Cells
11. Primetime Legal Services Agency Enters Agreement to Represent Trial Expert Dr. Ernest Chiodo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2019)... ... August 29, 2019 , ... ... in the Sustainable Medicines in Africa program, which includes a master’s degree in ... Arusha, Tanzania September 2nd through 13th, 2019. Topics to be addressed include ...
(Date:8/23/2019)... ... August 22, 2019 , ... The EnozoPro® converts ordinary tap ... harmful germs and pathogens on hard surfaces including E. Coli, Salmonella, MRSA, Listeria and ... residues. For more information, visit the product page at rovingblue.com , ”At Enozo, our ...
(Date:8/14/2019)... ... August 13, 2019 , ... Chata was founded ... QC laboratories. After gaining a few significant clients, Lifecycle purchased the company with ... supplier of manufacturing processing solutions, including reagents for tissue processing. Chata quickly outgrew ...
(Date:8/6/2019)... ... August 06, 2019 , ... ... populations down to the strain level, has announced partnerships with six international distributors. ... to companies and research organizations in Australia, Benelux, Indonesia, Korea, Malaysia, Myanmar, New ...
Breaking Biology Technology:
(Date:8/14/2019)... ... August 14, 2019 , ... Gateway Genomics , a leading developer ... in the 38th annual Inc. 500|5000 list of fastest growing private companies, ... must have been founded and generating revenue by March 31, 2015. Ranking in the ...
(Date:8/14/2019)... ... ... Reck of Veterinary Medical Center of Fort Mill has recently begun providing ... own geriatric Australian Shepherd, Simon, was treated in June 2019 for osteoarthritis in his shoulders, ... was weak, and he struggled to play fetch and other games with his family. ...
(Date:8/6/2019)... ... August 06, 2019 , ... A study released today ... have far-reaching implications for personalized medicine, especially when seeking treatments for children with ... predict which stem cell donors and manipulation methods might yield the best therapies ...
Breaking Biology News(10 mins):